COMMUNIQUÉS West-GlobeNewswire

CapsoVision Reports Second Quarter 2026 Financial Results
13/08/2026
SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported [...]
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
13/08/2026
PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf [...]
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
13/08/2026
Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline Data [...]
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
13/08/2026
Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026 Long-term Phase 2 BESTOW data presented at ATC 2026 [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13/08/2026
BEDFORD, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today [...]
Glass House Brands Reports Second Quarter 2026 Financial Results
13/08/2026
Second quarter results include record biomass production of 246,000 pounds and cost of production of $122 per pound, significant quarter-over-quarter improvements Company completed deconsolidation of its dual-use [...]
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
13/08/2026
RADNOR, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in [...]
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
13/08/2026
Achieved Q2 2026 PEMGARDA ® (pemivibart) net product revenue of $14.3 million, representing 21% growth versus Q2 2025 net product revenue of $11.8 million Completed rapid enrollment in VYD2311 DECLARATION clinical trial [...]
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third quarter 2026 [...]
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
13/08/2026
Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% [...]
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
13/08/2026
Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 - Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - Appointment of Farrell Simon, Pharm.D., to [...]
Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
13/08/2026
A patient-centered initiative focused on education, connection, and support TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage [...]
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
13/08/2026
Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding PONTE VEDRA, Fla., Aug. 13, 2026 ( [...]
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
13/08/2026
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated [...]
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
13/08/2026
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
13/08/2026
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates [...]
Tiny Health Named No. 208 on the 2026 Inc. 5000 List of America’s Fastest-Growing Private Companies
13/08/2026
Microbiome Innovator Recognized for 1,624% Three-Year Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tiny Health , the [...]
WellBridge Surgical Named No. 988 on the 2026 Inc. 5000 List, the Most Prestigious Ranking of America’s Fastest-Growing Private Companies
13/08/2026
Following Significant Revenue Growth Over the Past Three Years, Earning a Place Among the Nation’s Most Successful Independent Businesses INDIANAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- WellBridge Surgical today [...]
Rapport Semestriel 2026 Valneva
13/08/2026
Rapport Semestriel 2026 Valneva Pièce jointe Financial Report HY1 2026 (FR) (2026-08-12) (002)

Pages